Hospital
Three Rivers Health System, INC
Three Rivers Health System, INC was paid $13.42M by Medicaid between Jan 2018 and Nov 2024, across 222 billing codes. Its largest line is 99284, emergency room visit (serious) — 33% of everything it billed.
33Billing provider infoTHREE RIVERS HEALTH SYSTEM, INC
THREE RIVERS, MI 49093
THREE RIVERS, MI 49093
33aNPI1568739423assigned 11/21/2011
33bProvider typeGeneral Acute Care Hospital
28Total paid$13.42M
24GClaims408,315
24DCodes billed222
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#58 of 86
Median peer was paid$21.55M
This provider vs. median0.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official COSTELLO, JEFFERY controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 63,200 | $1.96M | |
| 2019 | 62,554 | $2.11M | |
| 2020 | 49,142 | $1.54M | |
| 2021 | 61,905 | $2.16M | |
| 2022 | 61,272 | $2.03M | |
| 2023 | 66,604 | $2.14M | |
| 2024incomplete | 43,638 | $1.46M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 33% | 24,179 | 22,502 | $4.40M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 13,204 | 12,666 | $1.64M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.2% | 3,543 | 3,379 | $1.23M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.6% | 6,342 | 5,865 | $616K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.4% | 7,679 | 6,101 | $460K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.0% | 2,661 | 2,570 | $405K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.0% | 17,442 | 5,122 | $404K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 2,704 | 2,019 | $238K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.5% | 2,718 | 2,664 | $201K |
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 5,343 | 5,180 | $200K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.4% | 6,076 | 5,356 | $193K |
| 59409 | Vaginal delivery only (with or without episiotomy and/or forceps) | 1.3% | 233 | 229 | $172K |
210 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 5,844 | $168K |
| 59025 | Fetal non-stress test | 1.0% | 1,537 | $141K |
| 80061 | Lipid panel | <1% | 7,421 | $131K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,444 | $123K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,005 | $96K |
| 99220 | <1% | 823 | $83K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,950 | $82K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,867 | $77K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,882 | $76K |
| 86900 | <1% | 2,024 | $76K | |
| G0378 | Hospital observation service, per hour | <1% | 415 | $76K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,391 | $75K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 3,613 | $74K |
| 76830 | Ultrasound, transvaginal | <1% | 1,208 | $71K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,205 | $69K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,724 | $68K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,878 | $68K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,395 | $68K |
| 87428 | <1% | 3,282 | $63K | |
| 80053 | Comprehensive metabolic panel | <1% | 23,701 | $62K |
| 97162 | <1% | 1,145 | $60K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 133 | $60K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,229 | $56K |
| 97161 | <1% | 1,080 | $54K | |
| 99460 | <1% | 955 | $50K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 408 | $47K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,717 | $44K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,497 | $41K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 24,868 | $39K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,398 | $38K |
| 64493 | <1% | 69 | $38K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 622 | $37K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,291 | $36K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 609 | $36K |
| 99223 | Prolong inpt eval add15 m | <1% | 361 | $35K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,109 | $35K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,231 | $34K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 23 | $32K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 728 | $30K |
| 59400 | Routine obstetric care including antepartum care, vaginal delivery, and postpartum care | <1% | 13 | $29K |
| 36415 | Collection of venous blood by venipuncture | <1% | 21,496 | $28K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 485 | $27K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 633 | $27K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 461 | $25K |
| 27687 | <1% | 55 | $24K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 103 | $22K |
| 72100 | <1% | 565 | $22K | |
| 86780 | <1% | 2,790 | $21K | |
| 76801 | <1% | 362 | $21K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,521 | $20K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 242 | $20K |
| 87481 | <1% | 990 | $19K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,185 | $18K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,310 | $17K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 486 | $14K |
| 86703 | <1% | 2,868 | $14K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 301 | $14K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,968 | $14K |
| 84439 | <1% | 2,938 | $13K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,703 | $13K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 295 | $13K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 161 | $12K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 194 | $11K |
| 84702 | <1% | 2,271 | $11K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,020 | $10K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 104 | $10K |
| 86803 | <1% | 2,137 | $10K | |
| 64483 | <1% | 25 | $9K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 83 | $9K |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 678 | $8K |
| 01480 | <1% | 111 | $8K | |
| 73630 | <1% | 987 | $7K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,394 | $7K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 750 | $7K |
| 87088 | <1% | 2,926 | $6K | |
| 87340 | <1% | 2,039 | $6K | |
| 87625 | <1% | 264 | $6K | |
| 85027 | <1% | 2,986 | $5K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 12 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,782 | $5K |
| 88142 | <1% | 494 | $5K | |
| 82728 | <1% | 774 | $5K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,943 | $5K |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 65 | $5K |
| 73610 | <1% | 717 | $4K | |
| 81001 | <1% | 13,540 | $4K | |
| 95851 | <1% | 494 | $4K | |
| 82043 | <1% | 1,292 | $4K | |
| 93975 | <1% | 39 | $4K | |
| 87077 | <1% | 1,141 | $4K | |
| 73030 | <1% | 324 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 363 | $4K |
| 83880 | <1% | 1,065 | $3K | |
| 82950 | <1% | 1,193 | $3K | |
| 83735 | <1% | 5,025 | $3K | |
| 82607 | <1% | 441 | $3K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 25 | $3K |
| 93971 | <1% | 53 | $3K | |
| 73130 | <1% | 543 | $3K | |
| 85610 | <1% | 2,693 | $3K | |
| 87070 | <1% | 817 | $3K | |
| 73562 | <1% | 226 | $2K | |
| 54150 | <1% | 36 | $2K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 14 | $2K |
| 70486 | <1% | 37 | $2K | |
| 87210 | <1% | 1,284 | $2K | |
| 87150 | <1% | 163 | $2K | |
| 73110 | <1% | 307 | $2K | |
| 76770 | <1% | 26 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,533 | $1K |
| 85651 | <1% | 957 | $1K | |
| 87186 | <1% | 466 | $1K | |
| 83540 | <1% | 386 | $1K | |
| 83690 | <1% | 4,373 | $1K | |
| 83550 | <1% | 268 | $1K | |
| 99217 | <1% | 30 | $1K | |
| 86317 | <1% | 866 | $926.51 | |
| 74018 | <1% | 48 | $872.96 | |
| 86140 | <1% | 561 | $854.59 | |
| 76536 | <1% | 12 | $781.25 | |
| 76641 | <1% | 12 | $779.55 | |
| 76642 | <1% | 15 | $682.69 | |
| 80306 | <1% | 797 | $634.42 | |
| 86850 | <1% | 1,752 | $605.81 | |
| 73502 | <1% | 28 | $562.26 | |
| 86677 | <1% | 143 | $550.32 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 25 | $509.74 |
| 84550 | <1% | 281 | $450.20 | |
| 86769 | <1% | 13 | $433.86 | |
| 81025 | <1% | 5,999 | $432.78 | |
| 87081 | <1% | 163 | $428.29 | |
| 86038 | <1% | 91 | $400.07 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 25 | $349.41 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 813 | $341.48 |
| 85730 | <1% | 1,300 | $339.45 | |
| 88304 | <1% | 115 | $310.08 | |
| 74019 | <1% | 263 | $288.86 | |
| 86694 | <1% | 20 | $279.08 | |
| 36591 | <1% | 17 | $273.35 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 29 | $257.96 |
| 82746 | <1% | 25 | $196.55 | |
| 85379 | <1% | 879 | $189.42 | |
| 83721 | <1% | 55 | $164.40 | |
| 86592 | <1% | 70 | $161.79 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 14 | $155.92 |
| 83605 | <1% | 3,945 | $154.55 | |
| 85652 | <1% | 177 | $124.71 | |
| 82105 | <1% | 12 | $94.24 | |
| 86704 | <1% | 25 | $90.31 | |
| 84484 | <1% | 4,075 | $88.64 | |
| 82570 | <1% | 35 | $78.73 | |
| 87040 | <1% | 835 | $66.62 | |
| 82550 | <1% | 119 | $60.96 | |
| 73564 | <1% | 15 | $59.64 | |
| 82784 | <1% | 27 | $57.45 | |
| 84703 | <1% | 226 | $50.59 | |
| 86756 | <1% | 486 | $39.84 | |
| 84403 | <1% | 13 | $29.40 | |
| 87807 | <1% | 373 | $29.17 | |
| 87430 | <1% | 313 | $28.59 | |
| 80076 | <1% | 15 | $26.82 | |
| 86431 | <1% | 12 | $25.52 | |
| 86709 | <1% | 12 | $25.26 | |
| 82150 | <1% | 26 | $24.42 | |
| 87205 | <1% | 12 | $23.40 | |
| 84146 | <1% | 13 | $12.74 | |
| 84132 | <1% | 13 | $2.78 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 1,426 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 190 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 4,496 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 3,350 | $0.00 |
| 86901 | 0% | 2,029 | $0.00 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 3,154 | $0.00 |
| 96376 | 0% | 1,578 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 2,534 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 851 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 201 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 1,170 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 29 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 518 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 322 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 27 | $0.00 |
| 82376 | 0% | 15 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 591 | $0.00 |
| 12001 | 0% | 61 | $0.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 60 | $0.00 |
| 64494 | 0% | 91 | $0.00 | |
| 94760 | 0% | 31 | $0.00 | |
| 96368 | 0% | 15 | $0.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 14 | $0.00 |
| 82962 | 0% | 54 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 37 | $0.00 |
| 97750 | 0% | 14 | $0.00 | |
| 95831 | 0% | 34 | $0.00 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 3,808 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 1,307 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 109 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 1,247 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 372 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 4,385 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 169 | $0.00 |
| 90715 | 0% | 212 | $0.00 | |
| 82948 | 0% | 304 | $0.00 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 66 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 59 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 34 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 12 | $0.00 |
| 93041 | 0% | 56 | $0.00 | |
| 73140 | 0% | 12 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOSTELLO, JEFFERY (CFO)
| Provider | Location | Paid |
|---|---|---|
| Three Rivers Health System, INC | Three Rivers, MI | $3.13M |
| Three Rivers Health System, INC | Three Rivers, MI | $1.20M |
| Three Rivers Health System, INC | White Pigeon, MI | $1.07M |
| Three Rivers Health System, INC | Three Rivers, MI | $503K |
| Three Rivers Health System, INC | Three Rivers, MI | $359K |
| Three Rivers Health System, INC | Portage, MI | $262K |
| Three Rivers Health System, INC | Marcellus, MI | $248K |
| Three Rivers Health System, INC | Three Rivers, MI | $244K |
| Three Rivers Health System, INC | Portage, MI | $62K |
| Three Rivers Health System, INC | Three Rivers, MI | $24K |
| Three Rivers Health System, INC | Three Rivers, MI | $13K |
| Three Rivers Health System, INC | Three Rivers, MI | $6K |
| Three Rivers Health System, INC | Three Rivers, MI | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.